Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Nov;111(14):1744–1748. doi: 10.1289/ehp.6332

Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice.

Petia P Simeonova 1, Tracy Hulderman 1, Dan Harki 1, Michael I Luster 1
PMCID: PMC1241717  PMID: 14594625

Abstract

Epidemiologic studies have shown an association between elevated arsenic levels in drinking water and an increased risk of atherosclerosis and vascular diseases. The studies presented here were performed to evaluate the atherogenic potential of arsenic using a well-established and controlled animal model of human atherosclerosis, mice deficient in apolipoprotein E (ApoE), and in vitro systems including primary human vascular cells. Wild-type and ApoE-deficient mice were exposed to 20 or 100 microg/mL sodium arsenite in drinking water for 24 weeks. As assessed morphometrically, the size of grossly discernible lesions covering the intimal area of aorta were increased significantly in arsenic-treated ApoE-deficient mice compared with nontreated transgenic mice. This effect was not associated with increased levels of serum cholesterol but was accompanied by an accumulation of arsenic in the vessel wall. Introduction of cocoa butter into the diet for 2 weeks resulted in higher serum cholesterol levels and only slight increases in the lesion size in control or arsenic-exposed ApoE-deficient mice. There were no lesions observed in the wild-type C57BL6 mice, resistant to atherosclerosis, whether they received arsenic or control drinking water. In vitro studies, including primary aorta endothelial or smooth muscle cells, were conducted to evaluate whether arsenic induces cellular mechanisms relevant to atherogenesis such as endothelial dysfunction, lipid oxidation, and smooth muscle cell proliferation. Arsenic treatment does not modulate endothelial cell-mediated lipid oxidation or smooth muscle cell proliferation but induced the expression of genes coding inflammatory mediators, including interleukin-8. Induction of endothelial inflammatory activity may play a role in arsenic-related vascular effects.

Full Text

The Full Text of this article is available as a PDF (363.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad M., Theofanidis P., Medford R. M. Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha. J Biol Chem. 1998 Feb 20;273(8):4616–4621. doi: 10.1074/jbc.273.8.4616. [DOI] [PubMed] [Google Scholar]
  2. Axelson O., Dahlgren E., Jansson C. D., Rehnlund S. O. Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. Br J Ind Med. 1978 Feb;35(1):8–15. doi: 10.1136/oem.35.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barchowsky A., Dudek E. J., Treadwell M. D., Wetterhahn K. E. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 1996;21(6):783–790. doi: 10.1016/0891-5849(96)00174-8. [DOI] [PubMed] [Google Scholar]
  4. Barchowsky A., Klei L. R., Dudek E. J., Swartz H. M., James P. E. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med. 1999 Dec;27(11-12):1405–1412. doi: 10.1016/s0891-5849(99)00186-0. [DOI] [PubMed] [Google Scholar]
  5. Breslow J. L. Mouse models of atherosclerosis. Science. 1996 May 3;272(5262):685–688. doi: 10.1126/science.272.5262.685. [DOI] [PubMed] [Google Scholar]
  6. Bunderson Melisa, Coffin J. Douglas, Beall Howard D. Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol. 2002 Oct 1;184(1):11–18. [PubMed] [Google Scholar]
  7. Burleson F. G., Simeonova P. P., Germolec D. R., Luster M. I. Dermatotoxic chemical stimulate of c-jun and c-fos transcription and AP-1 DNA binding in human keratinocytes. Res Commun Mol Pathol Pharmacol. 1996 Aug;93(2):131–148. [PubMed] [Google Scholar]
  8. Chen C. J., Chiou H. Y., Chiang M. H., Lin L. J., Tai T. Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):504–510. doi: 10.1161/01.atv.16.4.504. [DOI] [PubMed] [Google Scholar]
  9. Chen C. J., Wu M. M., Lee S. S., Wang J. D., Cheng S. H., Wu H. Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988 Sep-Oct;8(5):452–460. doi: 10.1161/01.atv.8.5.452. [DOI] [PubMed] [Google Scholar]
  10. Chen G. S., Asai T., Suzuki Y., Nishioka K., Nishiyama S. A possible pathogenesis for Blackfoot disease--effects of trivalent arsenic (As2O3) on cultured human umbilical vein endothelial cells. J Dermatol. 1990 Oct;17(10):599–608. doi: 10.1111/j.1346-8138.1990.tb01703.x. [DOI] [PubMed] [Google Scholar]
  11. Daugherty A., Manning M. W., Cassis L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000 Jun;105(11):1605–1612. doi: 10.1172/JCI7818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Enterline P. E., Marsh G. M. Cancer among workers exposed to arsenic and other substances in a copper smelter. Am J Epidemiol. 1982 Dec;116(6):895–911. doi: 10.1093/oxfordjournals.aje.a113492. [DOI] [PubMed] [Google Scholar]
  13. Flohé L., Brigelius-Flohé R., Saliou C., Traber M. G., Packer L. Redox regulation of NF-kappa B activation. Free Radic Biol Med. 1997;22(6):1115–1126. doi: 10.1016/s0891-5849(96)00501-1. [DOI] [PubMed] [Google Scholar]
  14. Gairola C. G., Drawdy M. L., Block A. E., Daugherty A. Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E-/- mice. Atherosclerosis. 2001 May;156(1):49–55. doi: 10.1016/s0021-9150(00)00621-3. [DOI] [PubMed] [Google Scholar]
  15. Germolec D. R., Spalding J., Yu H. S., Chen G. S., Simeonova P. P., Humble M. C., Bruccoleri A., Boorman G. A., Foley J. F., Yoshida T. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol. 1998 Dec;153(6):1775–1785. doi: 10.1016/S0002-9440(10)65692-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gerszten R. E., Garcia-Zepeda E. A., Lim Y. C., Yoshida M., Ding H. A., Gimbrone M. A., Jr, Luster A. D., Luscinskas F. W., Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999 Apr 22;398(6729):718–723. doi: 10.1038/19546. [DOI] [PubMed] [Google Scholar]
  17. Hsueh Y. M., Wu W. L., Huang Y. L., Chiou H. Y., Tseng C. H., Chen C. J. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis. 1998 Dec;141(2):249–257. doi: 10.1016/s0021-9150(98)00178-6. [DOI] [PubMed] [Google Scholar]
  18. Koch A. E., Polverini P. J., Kunkel S. L., Harlow L. A., DiPietro L. A., Elner V. M., Elner S. G., Strieter R. M. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992 Dec 11;258(5089):1798–1801. doi: 10.1126/science.1281554. [DOI] [PubMed] [Google Scholar]
  19. Lee A. M., Fraumeni J. F., Jr Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst. 1969 Jun;42(6):1045–1052. [PubMed] [Google Scholar]
  20. Lee Moo-Yeol, Bae Ok-Nam, Chung Seung-Min, Kang Kyu-Tae, Lee Joo-Young, Chung Jin-Ho. Enhancement of platelet aggregation and thrombus formation by arsenic in drinking water: a contributing factor to cardiovascular disease. Toxicol Appl Pharmacol. 2002 Mar 1;179(2):83–88. doi: 10.1006/taap.2001.9356. [DOI] [PubMed] [Google Scholar]
  21. Lindgren A., Vahter M., Dencker L. Autoradiographic studies on the distribution of arsenic in mice and hamsters administered 74As-arsenite or -arsenate. Acta Pharmacol Toxicol (Copenh) 1982 Sep;51(3):253–265. doi: 10.1111/j.1600-0773.1982.tb01023.x. [DOI] [PubMed] [Google Scholar]
  22. Lloyd A. R., Oppenheim J. J., Kelvin D. J., Taub D. D. Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. J Immunol. 1996 Feb 1;156(3):932–938. [PubMed] [Google Scholar]
  23. Nakashima Y., Plump A. S., Raines E. W., Breslow J. L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994 Jan;14(1):133–140. doi: 10.1161/01.atv.14.1.133. [DOI] [PubMed] [Google Scholar]
  24. Palinski W., Ord V. A., Plump A. S., Breslow J. L., Steinberg D., Witztum J. L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994 Apr;14(4):605–616. doi: 10.1161/01.atv.14.4.605. [DOI] [PubMed] [Google Scholar]
  25. Pi Jingbo, Yamauchi Hiroshi, Kumagai Yoshito, Sun Guifan, Yoshida Takahiko, Aikawa Hiroyuki, Hopenhayn-Rich Claudia, Shimojo Nobuhiro. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect. 2002 Apr;110(4):331–336. doi: 10.1289/ehp.02110331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115–126. doi: 10.1056/NEJM199901143400207. [DOI] [PubMed] [Google Scholar]
  27. Rossman T. G., Uddin A. N., Burns F. J., Bosland M. C. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64–71. doi: 10.1006/taap.2001.9277. [DOI] [PubMed] [Google Scholar]
  28. Schreiber E., Matthias P., Müller M. M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 1989 Aug 11;17(15):6419–6419. doi: 10.1093/nar/17.15.6419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Simeonova P. P., Luster M. I. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms? J Environ Pathol Toxicol Oncol. 2000;19(3):281–286. [PubMed] [Google Scholar]
  30. Simeonova P. P., Toriumi W., Kommineni C., Erkan M., Munson A. E., Rom W. N., Luster M. I. Molecular regulation of IL-6 activation by asbestos in lung epithelial cells: role of reactive oxygen species. J Immunol. 1997 Oct 15;159(8):3921–3928. [PubMed] [Google Scholar]
  31. Simeonova P. P., Wang S., Toriuma W., Kommineni V., Matheson J., Unimye N., Kayama F., Harki D., Ding M., Vallyathan V. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res. 2000 Jul 1;60(13):3445–3453. [PubMed] [Google Scholar]
  32. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915–924. doi: 10.1056/NEJM198904063201407. [DOI] [PubMed] [Google Scholar]
  33. Terkeltaub R., Boisvert W. A., Curtiss L. K. Chemokines and atherosclerosis. Curr Opin Lipidol. 1998 Oct;9(5):397–405. doi: 10.1097/00041433-199810000-00003. [DOI] [PubMed] [Google Scholar]
  34. Tsai S. H., Hsieh M. S., Chen L., Liang Y. C., Lin J. K., Lin S. Y. Suppression of Fas ligand expression on endothelial cells by arsenite through reactive oxygen species. Toxicol Lett. 2001 Aug 6;123(1):11–19. doi: 10.1016/s0378-4274(01)00373-3. [DOI] [PubMed] [Google Scholar]
  35. Tseng W. P. Blackfoot disease in Taiwan: a 30-year follow-up study. Angiology. 1989 Jun;40(6):547–558. doi: 10.1177/000331978904000606. [DOI] [PubMed] [Google Scholar]
  36. Wall S. Survival and mortality pattern among Swedish smelter workers. Int J Epidemiol. 1980 Mar;9(1):73–87. doi: 10.1093/ije/9.1.73. [DOI] [PubMed] [Google Scholar]
  37. Wang Chih-Hao, Jeng Jiann-Shing, Yip Ping-Keung, Chen Chi-Ling, Hsu Lin-I, Hsueh Yu-Mei, Chiou Hung-Yi, Wu Meei-Mann, Chen Chien-Jen. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 2002 Apr 16;105(15):1804–1809. doi: 10.1161/01.cir.0000015862.64816.b2. [DOI] [PubMed] [Google Scholar]
  38. Weiss D., Kools J. J., Taylor W. R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2001 Jan 23;103(3):448–454. doi: 10.1161/01.cir.103.3.448. [DOI] [PubMed] [Google Scholar]
  39. Welch K., Higgins I., Oh M., Burchfiel C. Arsenic exposure, smoking, and respiratory cancer in copper smelter workers. Arch Environ Health. 1982 Nov-Dec;37(6):325–335. doi: 10.1080/00039896.1982.10667586. [DOI] [PubMed] [Google Scholar]
  40. Witztum J. L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991 Dec;88(6):1785–1792. doi: 10.1172/JCI115499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Wu M. M., Kuo T. L., Hwang Y. H., Chen C. J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989 Dec;130(6):1123–1132. doi: 10.1093/oxfordjournals.aje.a115439. [DOI] [PubMed] [Google Scholar]
  42. Yamauchi H., Yamamura Y. Concentration and chemical species of arsenic in human tissue. Bull Environ Contam Toxicol. 1983 Sep;31(3):267–270. doi: 10.1007/BF01608697. [DOI] [PubMed] [Google Scholar]
  43. Yue T. L., Mckenna P. J., Gu J. L., Feuerstein G. Z. Interleukin-8 is chemotactic for vascular smooth muscle cells. Eur J Pharmacol. 1993 Aug 10;240(1):81–84. doi: 10.1016/0014-2999(93)90549-w. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES